The outbreak of coronavirus disease 2019 (COVID-19) rapidly spreads across worldwide and becomes a global pandemic. Remdesivir is the only COVID-19 treatment approved by U.S. Food and Drug Administration (FDA); however, its effectiveness is still...
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Près d'un an après que l'on a identifié le coronavirus SARS-CoV-2, les chercheurs n'ont toujours pas déterminé comment il a pu se transmettre à l'espèce humaine. Le virologue Étienne Decroly fait le point sur les différentes hypothèses, dont celle...
Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11...
Objective: To examine the association between hydroxyzine use and mortality in patients hospitalized for COVID-19, based on its anti-inflammatory and antiviral properties. Design: Multicenter observational retrospective cohort study. Setting:...
Julien PotetRough times for the strategy of "passive immunization" against #COVID19.
Negative results in hospitalized patients for both convalescent plasma (PLACID RCT, India) & @LillyPad's LY-CoV555 (aka bamlanivimab) (ACTIV-3 RCT, US)
lilly.com/news/stories/s…bmj.com/content/371/bm…
87d
Author summary Snakebite is a neglected tropical disease which has received priority attention in the global health space with WHO setting a target to decrease death and disability due to snakebite to 50% by 2030. High quality systematic reviews can...
Background: The 2019 novel coronavirus disease (Covid-19) worldwide pandemic has posed the most substantial and severe public health issue for several generatio
The antiparasitic drug nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on SARS-CoV-2 infection. In a multicenter, randomized, double-blind, placebo-controlled trial,...
Objective To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.
Design Open label, parallel arm, phase II, multicentre, randomised controlled trial.
Setting 39...
Julien PotetRough times for the strategy of "passive immunization" against #COVID19.
Negative results in hospitalized patients for both convalescent plasma (PLACID RCT, India) & @LillyPad's LY-CoV555 (aka bamlanivimab) (ACTIV-3 RCT, US)
lilly.com/news/stories/s…bmj.com/content/371/bm…
87d
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Partners aim to provide potent neutralizing...
COVID-19 has become a global epidemic, and effective therapies have not been discovered up to now. We conducted this study to explore the effectiveness and safety of tocilizumab recently used for treating COVID-19. A comprehensive search was...
This randomized clinical trial evaluates the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19.
An inhaled neutralizing antibody cleared the novel coronavirus from infected hamsters at a far lower dose compared with other experimental monoclonal antibodies. The drug is now being developed by Aridis Pharmaceuticals and could offer a...
Julien PotetWhile @Regeneron is pushing its high-dose IV anti-SARS2 mAb cocktail (8g !!), researchers are developing inhaled low-dose anti-SARS2 mAbs (2mg-6mg !!). Potentially much cheaper and more user-friendly!
93d
Background: Mortality attributable to coronavirus disease-19 (COVID-19) 2 infection occurs mainly through the development of viral pneumonia-induced acute respiratory distress syndrome (ARDS). Research Question: The objective of the study is to...
Nitazoxanide demonstrates a good safety profile at approved doses. However, further evidence is required regarding hepatorenal and cardiovascular effects, as well as teratogenicity. We estimate that it would be possible to manufacture nitazoxanide...
In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment for COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to...
Julien PotetPre-print: @UniversidadCR in Costa Rica shares the full recipe for their therapeutic equine antiserum for #SARSCoV2. No patent, no trade secret. Other manufacturers can now produce similar products if they wish.
This is open science in practice !
94d